Literature DB >> 1650535

Experience with 225 hepatic resections for hepatocellular carcinoma over a 4-year period.

K Ozawa1, T Takayasu, K Kumada, Y Yamaoka, K Tanaka, N Kobayashi, T Inamoto, Y Shimahara, K Mori, K Honda.   

Abstract

During the past 4 1/2 years, we have performed hepatic resection on 225 patients with hepatocellular carcinoma (HCC). These patients included 171 men and 54 women, whose ages ranged from 29 to 84 years with an average of 60 years. Underlying cirrhosis of the liver was found in 67% of the patients and chronic hepatitis in 27%. Patients undergoing hepatic resection were classified into five groups according to curability as follows: Group A, resection of the tumor-bearing segment and one additional segment; Group B, complete resection of the tumor with more than 1.0 cm free surgical margin; Group C, complete resection of the tumor with less than 1.0 cm free surgical margin; Group D, incomplete resection of the tumor; Group E, surgical approach for advanced HCC with tumor thrombi in the main trunk or the first branch of the portal vein and/or the inferior vena cava, with multiple daughter nodules in both lobes and with tumor recurrence. The number of patients in Groups A, B, C, D, and E was 12 (5%), 83 (37%), 58 (26%), 14 (6%) and 58, (26%), respectively. There were 4 deaths (2.4%) among the 167 patients in Groups A to D within 30 days after operation and 12 deaths (20.7%) in Group E. The 3-year survival rate of Groups A, B, C, D, and E was 100%, 74%, 21%, 0%, and 35%, respectively.

Entities:  

Mesh:

Year:  1991        PMID: 1650535     DOI: 10.1016/0002-9610(91)91254-g

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  11 in total

1.  Prognostic impact of anatomic resection for hepatocellular carcinoma.

Authors:  Kiyoshi Hasegawa; Norihiro Kokudo; Hiroshi Imamura; Yutaka Matsuyama; Taku Aoki; Masami Minagawa; Keiji Sano; Yasuhiko Sugawara; Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

2.  Laparoscopy and laparoscopic ultrasonography avoid exploratory laparotomy in patients with hepatocellular carcinoma.

Authors:  C M Lo; E C Lai; C L Liu; S T Fan; J Wong
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  Hepatitis B or C virus serology as a prognostic factor in patients with hepatocellular carcinoma.

Authors:  S A Ahmad; M M Bilimoria; X Wang; F Izzo; P Delrio; P Marra; T P Baker; G A Porter; L M Ellis; J N Vauthey; S Dhamotharan; S A Curley
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

4.  Is preoperative hepatic arterial chemoembolization safe and effective for hepatocellular carcinoma?

Authors:  T Harada; K Matsuo; T Inoue; S Tamesue; T Inoue; H Nakamura
Journal:  Ann Surg       Date:  1996-07       Impact factor: 12.969

Review 5.  Management of hepatocellular carcinoma.

Authors:  Janice N Cormier; K Tyson Thomas; Ravi S Chari; C Wright Pinson
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

6.  Hepatocellular carcinoma with adjacent organ extension: the enhancement of preoperative transcatheter arterial embolization and the results of surgical resection.

Authors:  C C Wu; W L Ho; T J Liu
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 7.  [Liver resections for primary liver malignancies. Personal results and analysis of the literature].

Authors:  J Zieren; H U Zieren; J M Müller
Journal:  Langenbecks Arch Chir       Date:  1994

8.  Clinical Impact of Anatomical Liver Resection for Hepatocellular Carcinoma with Pathologically Proven Portal Vein Invasion.

Authors:  Takatsugu Matsumoto; Keiichi Kubota; Taku Aoki; Yukihiro Iso; Masato Kato; Mitsugi Shimoda
Journal:  World J Surg       Date:  2016-02       Impact factor: 3.352

9.  En bloc resection for extensive hepatocellular carcinoma: is it advisable?

Authors:  K S Jeng; B F Chen; H J Lin
Journal:  World J Surg       Date:  1994 Nov-Dec       Impact factor: 3.352

10.  Early mortality in 100 consecutive liver resections in 96 patients with benign and malignant liver tumours.

Authors:  N A Habib
Journal:  Ann R Coll Surg Engl       Date:  1995-03       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.